Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

Blood. 2015 May 21;125(21):3360-3. doi: 10.1182/blood-2015-03-632893.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Calreticulin / genetics*
  • Dasatinib
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Male
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Thiazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Calreticulin
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Fusion Proteins, bcr-abl
  • Dasatinib